Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 18/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202861 | 0.90 | ESR1 (0.50) | ESR1ESR2HSP90AA1MEN1ALDH1A1 | |
| SCHEMBL2198400 | 0.90 | ESR1 (0.49) | ESR1ESR2HSP90AA1MEN1ALDH1A1 | |
| SCHEMBL2397089 | 0.87 | ESR1 (0.46) | ESR1ESR2HSP90AA1MEN1ALDH1A1 | |
| SCHEMBL2197946 | 0.86 | ESR1 (0.45) | ESR1ESR2HSP90AA1MEN1ALDH1A1 | |
| SCHEMBL1939644 | 0.73 | HSP90AB1 (0.56) | ESR1ESR2HSP90AA1 | |
| SCHEMBL1941841 | 0.72 | SLC6A4 (0.36) | MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL4402156 | 0.68 | ESR1 (0.44) | ESR1ESR2HSP90AA1MEN1ALDH1A1 | |
| SCHEMBL12589320 | 0.67 | ESR1 (0.53) | ESR1ESR2HSP90AA1ALDH1A1 | |
| SCHEMBL15653285 | 0.66 | ADRB2 (0.44) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL29597586 | 0.65 | EGFR (0.60) | ESR1HSP90AA1EGFRMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977364-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2011-07-12 | — | — | US | claimed |
| US-8173679-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2012-05-08 | — | — | US | disclosed |
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | ESR1, ESR2, GPER1 | ESR1 1/4885ESR2 2/4885HSP90AA1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.